WallStreetZenWallStreetZen

NASDAQ: RXST
Rxsight Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for RXST

Based on 2 analysts offering 12 month price targets for Rxsight Inc.
Min Forecast
$14.00+23.02%
Avg Forecast
$18.00+58.17%
Max Forecast
$22.00+93.32%

Should I buy or sell RXST stock?

Based on 2 analysts offering ratings for Rxsight Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RXST stock forecasts and price targets.

RXST stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Needham
Bottom 9%
9
BuyMaintains$22.00+93.32%2022-08-09
SVB Leerink
Bottom 3%
3
BuyMaintains$14.00+23.02%2022-05-06

1 of 1

Forecast return on equity

Is RXST forecast to generate an efficient return?
Company
-56.29%
Industry
24.32%
Market
118.57%
RXST's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RXST forecast to generate an efficient return on assets?
Company
-37.14%
Industry
13.22%
RXST is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RXST earnings per share forecast

What is RXST's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$2.70
Avg 2 year Forecast
-$2.59
Avg 3 year Forecast
-$2.37

RXST revenue forecast

What is RXST's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$45.1M+30.56%
Avg 2 year Forecast
$75.2M+117.74%
Avg 3 year Forecast
$95.6M+177.1%
RXST's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RXST revenue growth forecast

How is RXST forecast to perform vs Medical Devices companies and vs the US market?
Company
41.24%
Industry
4.76%
Market
8.46%
RXST's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RXST's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RXST vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
RXST$11.38$18.00+58.17%Buy
QTRX$8.47$26.25+209.92%Hold
SGHT$6.61$18.50+179.88%Strong Buy
MDXG$2.74$8.00+191.97%Buy
ZYXI$8.39$20.00+138.38%Buy

Rxsight Stock Forecast FAQ

Is Rxsight Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: RXST) stock is to Buy RXST stock.

Out of 2 analysts, 0 (0%) are recommending RXST as a Strong Buy, 2 (100%) are recommending RXST as a Buy, 0 (0%) are recommending RXST as a Hold, 0 (0%) are recommending RXST as a Sell, and 0 (0%) are recommending RXST as a Strong Sell.

If you're new to stock investing, here's how to buy Rxsight stock.

What is RXST's earnings growth forecast for 2022-2024?

(NASDAQ: RXST) Rxsight's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 19.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.42%.

Rxsight's earnings in 2022 is -$62,735,000.On average, 1 Wall Street analyst forecast RXST's earnings for 2022 to be -$74,625,027, with the lowest RXST earnings forecast at -$74,625,027, and the highest RXST earnings forecast at -$74,625,027. On average, 1 Wall Street analyst forecast RXST's earnings for 2023 to be -$71,584,748, with the lowest RXST earnings forecast at -$71,584,748, and the highest RXST earnings forecast at -$71,584,748.

In 2024, RXST is forecast to generate -$65,504,191 in earnings, with the lowest earnings forecast at -$65,504,191 and the highest earnings forecast at -$65,504,191.

What is RXST's revenue growth forecast for 2022-2024?

(NASDAQ: RXST) Rxsight's forecast annual revenue growth rate of 41.24% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 4.76%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.46%.

Rxsight's revenue in 2022 is $34,514,000.On average, 1 Wall Street analysts forecast RXST's revenue for 2022 to be $1,245,408,789, with the lowest RXST revenue forecast at $1,245,408,789, and the highest RXST revenue forecast at $1,245,408,789. On average, 1 Wall Street analysts forecast RXST's revenue for 2023 to be $2,077,063,260, with the lowest RXST revenue forecast at $2,077,063,260, and the highest RXST revenue forecast at $2,077,063,260.

In 2024, RXST is forecast to generate $2,643,384,300 in revenue, with the lowest revenue forecast at $2,643,384,300 and the highest revenue forecast at $2,643,384,300.

What is RXST's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: RXST) forecast ROA is -37.14%, which is lower than the forecast US Medical Devices industry average of 13.22%.

What is RXST's Price Target?

According to 2 Wall Street analysts that have issued a 1 year RXST price target, the average RXST price target is $18.00, with the highest RXST stock price forecast at $22.00 and the lowest RXST stock price forecast at $14.00.

On average, Wall Street analysts predict that Rxsight's share price could reach $18.00 by Aug 9, 2023. The average Rxsight stock price prediction forecasts a potential upside of 58.17% from the current RXST share price of $11.38.

What is RXST's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: RXST) Rxsight's current Earnings Per Share (EPS) is -$1.84. On average, analysts forecast that RXST's EPS will be -$2.70 for 2022, with the lowest EPS forecast at -$2.70, and the highest EPS forecast at -$2.70. On average, analysts forecast that RXST's EPS will be -$2.59 for 2023, with the lowest EPS forecast at -$2.59, and the highest EPS forecast at -$2.59. In 2024, RXST's EPS is forecast to hit -$2.37 (min: -$2.37, max: -$2.37).

What is RXST's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: RXST) forecast ROE is -56.29%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.